UNSPSC 51172163: Bietamiverine hydrochloride

This classification denotes an antispasmotic agent and antimuscarinic agent with the molecular formula C19H30N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 646WTQ0G3E, chemically known as 1-piperidineacetic acid, alpha-phenyl-, 2-(diethylamino)ethyl ester, hydrochloride but more generally known as bietamiverine hydrochloride, which bears US NIH Compound Identifier 72063. Most nations, for tariff and trade purposes, schedule bietamiverine hydrochloride under HS 29333999.

As of Q4 2014, BIETAMIVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Bietamiverine hydrochloride bears US NLM NCI C73602. SMILES: CCN(CC)CCOC(=O)C(C1CCCCC1)N2CCCCC2.CL.

UNSPSC 51172163 Bietamiverine hydrochloride is a Commodity code that does not match the state and local procurement activity posted under it. The single recent opportunity available — Collin County Community Supervision and Corrections Department's RFP for offender specimen collection and drug testing services — involves laboratory testing infrastructure, staffing, and reporting systems for criminal-justice drug screening, with no connection to bietamiverine hydrochloride or pharmaceutical procurement. The code shows little relevant recent activity aligned with its nominal pharmaceutical scope.

Collin County CSCD issued RFP 2026-327 with proposals due July 23, 2026, seeking a vendor to operate two collection sites in Plano and McKinney, manage randomized testing notifications via Interactive Voice Response, perform immunoassay and confirmatory testing (LC/MS/MS or GC/MS), and report results electronically. The contract, valued at approximately $600,000, runs two years from September 1, 2026, with three optional one-year renewal periods. The vendor must hold SAMHSA, Texas DPS, or CAP lab certification and price services on a per-test basis across three models: screening only, confirmation after screening, and screening with automatic confirmation of positives. The county anticipates awarding by August 10, 2026. This single posting does not establish a pattern of state and local demand under the code; procurement professionals should verify whether bietamiverine hydrochloride appears in active state or local solicitations beyond the misclassified drug-testing RFP currently tagged to this commodity code.